|Mr. Peter Jonathan Butterfield||CEO & Exec. Director||328.99k||N/A||1976|
|Mr. John Dawson||Founder & Non-Exec. Director||292.86k||N/A||1949|
|Mr. Andrew Timothy Franklin||CFO & Exec. Director||241.9k||N/A||1966|
|Mr. Stephen Kidner||Chief Scientific & Operations Officer||N/A||N/A||N/A|
|Mr. Daniel Thomas||Chief Corp. Devel. Officer||N/A||N/A||N/A|
Alliance Pharma plc operates as a specialty pharmaceutical company in the United Kingdom, rest of Europe, and internationally. The company acquires, markets, and sells pharmaceutical products. It acquires the rights of established products, and owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The company also provides prescription only medicines, over the counter medications, cosmetics, and nutritional supplements, as well as medical devices. In addition, it offers products in various therapeutic areas, including acquired healthcare, cardiovascular, central nervous system, child health, consumer health, dermatology, endocrinology, gastroenterology, obstetrics and gynecology, oral health, oncology, stoma care, toxicology, travel health, urology, vitamins and minerals, and others. Further, the company provides the Kelo-Cote, a formula silicone treatment used for prevention and forming of scars; MacuShield, an eye care supplement; and Vamousse, a pesticide free consumer healthcare product for prevention and treatment of human heal lice. The company distributes its products through wholesalers, retail pharmacies, hospitals, and network of distributors. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Alliance Pharma plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.